Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Bioengineering
Researchers from Imperial College London detail new studies and findings in the area of bioengineering
March 13th, 2008
Research findings, 'STX140 is efficacious in vitro and in vivo in taxane-resistant breast carcinoma cells,' are discussed in a new report. "The aim of these studies was to characterize the action of STX140 in a P-glycoprotein-overexpressing tumor cell line both in vitro and in vivo. In addition, its efficacy was determined against xenografts derived from patients who failed docetaxel therapy," investigators in London, the United Kingdom report. "The effects of STX140, Taxol, and 2-methoxyestradiol (2-MeOE2) on cell proliferation, cell cycle, and apoptosis were assessed in vitro in drug-resistant cells (MCF-7(DOX)) and the parental cell line (MCF-7(WT)). Mice bearing an...
Source: Women's Health Weekly (2008-03-13)
|
